For example, in triple-negative breast cancer (TNBC), a phase I clinical trial is testing the effect of chemotherapy combining alpelisib with enzalutamide in AR+ and PTEN+ breast cancer, including a cohort of TNBC (NCT03207529). Here, PTEN is linked to breast cancer.